As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/31/15  Nymox Pharmaceutical Corp         20-F       12/31/14    6:1.2M                                   e3 Fil… Computershare/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report for the Fiscal Year Ended December    HTML    980K 
                          31, 2014                                               
 2: EX-4.X      6% Secured Convertible Note Dated December 16,      HTML     53K 
                          2014                                                   
 5: EX-13.A     Sox Section 906 CEO Certification                   HTML      6K 
 6: EX-13.B     Sox Section 906 CFO Certification                   HTML      6K 
 3: EX-12.A     Sox Section 302 CEO Certification                   HTML     10K 
 4: EX-12.B     Sox Section 302 CFO Certification                   HTML     10K 

CERTIFICATION

I, Andre Monette, certify that:

1.	I have reviewed this annual report on Form 20-F of Nymox Pharmaceutical Corporation;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Corporation as of, and for, the periods presented in this report;
4.	The Corporation’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)), and internal control over financial reporting (as defined in the Exchange Act Rules 13a–15(f) and 15d–15(f)) for the Corporation based on the COSO 1992 framework and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Corporation, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the Corporation’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the Corporation’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Corporation’s internal control over financial reporting; and

5.	The Corporation’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Corporation’s auditors and the audit committee of the Corporation’s board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Corporation’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Corporation’s internal control over financial reporting.

Date: March 31, 2015

/s/ Andre Monette
Andre Monette
Chief Financial Officer
Nymox Pharmaceutical Corporation

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/21/16  SEC                               UPLOAD¶     9/27/17    1:35K  Nymox Pharmaceutical Corp.